Summary
Serum cefotaxime and desacetylcefotaxime concentrations and their tissue concentrations in the kidney were determined at 30 minutes after cefotaxime (80 mg/kg) bolus intravenous infusion in rabbits when the urinary tract was obstructed. Serum concentration was highest in bilateral ureteral obstruction (BUO) animals (142.1 ± 25.4 mg/L), followed in order by unilateral ureteral obstruction (UUO) animals (92.6 ± 10.4 mg/L) and sham-operated animals (50.4 ±9.9 mg/L). Both serum cefotaxime and desacetylcefotaxime concentrations were highly correlated with serum creatinine levels. Conversely, the renal tissue/serum concentration ratio of cefotaxime and its metabolite was lowest in BUO animals, which was in accordance with physiological evidence that renal blood flow was reduced in BUO. Indomethacin pretreatment exaggerated cefotaxime and desacetylcefotaxime accumulation in the obstructed kidney of the UUO model, indicating that this drug inhibits renal elimination of cefotaxime when urinary tract obstruction exists.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Aratani H, Tateishi H, Nesota J, Yamanaka Y. Pharmacokinetics of cefotaxime. Chemotherapy 28: 65–72, 1980
Chamberlain J, Coomes JD, Dell D, Fromson JM, Ings RJ, et al. Metabolism of cefotaxime in animals and man. Journal of Antimicrobial Chemotherapy 6 (Suppl. A): 69–78, 1980
Esmieu F, Guilbert J, Rosenkidle HC, Ho I, Le Go A. Pharmacokinetics of cefotaxime in normal human volunteers. Journal of Antimicrobial Chemotherapy 6 (Suppl. A): 83–92, 1980
Fu KP, Aswapokee P, Ho I, Matthijssen C, Neu HC. Pharmacokinetics of cefotaxime. Antimicrobial Agents and Chemotherapy 16: 592–597, 1979
Kondoh K, Matsumoto S, Ohashi Y, Kamei Y, Hirano M, et al. Pharmacokinetics of cefotaxime in patients with renal dysfunction. Chemotherapy 31: 969–974, 1983
Lüthy R, Münch R, Blaser J, Bhend H, Siegenthaler W. Human pharmacology of cefotaxime (HR 756), a new cephalosporin. Antimicrobial Agents and Chemotherapy 16: 127–133, 1979
Moody TE, Vaughan Jr ED, Gillenwater JY. Relationship between renal blood flow and ureteral pressure during 18 hours of total unilateral ureteral occlusion. Implications for changing sites of increased renal resistance. Investigative Urology 13: 246–251, 1975
Ohkawa M, Tokunaga S, Shyoda Y, Kawaguchi S, Sawaki M, et al. Pharmacokinetics and metabolism of cefotaxime in renal failure. Chemotherapy 29: 589–597, 1981
Reeves DS, White LO, Holt HA, Bahari D, Bywater MJ, et al. Human metabolism of cefotaxime. Journal of Antimicrobial Chemotherapy 6 (Suppl. A): 93–101, 1980
Skeith MD, Simkin PA, Healey LA. The renal excretion of indomethacin and its inhibition by probenecid. Clinical Pharmacology and Therapeutics 9: 89–93, 1967
Vaughan ED, Sorenson EJ, Gilleuwater JY. The renal hemodynamic response to chronic unilateral ureteral occlusion. Investigative Urology 8: 78–90, 1970
Yarger WE, Harris RH. Urinary tract obstruction. In Seldin & Giebish (Eds) The kidney: physiology and pathophysiology, pp. 1963–1978, Raven Press, New York, 1985
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Tago, K., Yabusaki, N. & Ueno, A. Serum and Renal Tissue Concentrations of Cefotaxime in Urinary Tract Obstruction in Rabbits. Drugs 35 (Suppl 2), 65–71 (1988). https://doi.org/10.2165/00003495-198800352-00015
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800352-00015